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a b s t r a c t
Ethics on animal use in science in Western society is based on utilitarianism, weighing the harms and
benefits to the animals involved against those of the intended human beneficiaries. The 3Rs concept
(Replacement, Reduction, Refinement) is both a robust framework for minimizing animal use and
suffering (addressing the harms to animals) and a means of supporting high quality science and
translation (addressing the benefits). The ambiguity of basic research performed early in the research
continuum can sometimes make harm-benefit analysis more difficult since anticipated benefit is often
an incremental contribution to a field of knowledge. On the other hand, benefit is much more evident in
translational research aimed at developing treatments for direct application in humans or animals
suffering from disease. Though benefit may be easier to define, it should certainly not be considered
automatic. Issues related to model validity seriously compromise experiments and have been implicated
as a major impediment in translation, especially in complex disease models where harms to animals can
be intensified. Increased investment and activity in the 3Rs is delivering new research models, tools and
approaches with reduced reliance on animal use, improved animal welfare, and improved scientific and
predictive value.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Scientific advances have made it possible to better diagnose
and treat a number of diseases in both human and veterinary
medicine bringing about substantial improvement in quality of life
(QOL) for these patients. Because of the pivotal contribution of
animal experiments to this work, animals are often used for
biomedical research and development worldwide. Besides funda-
mental research on pathophysiological processes, the major part
focuses on discovery and development of new medical entities
such as drugs, biologicals, devices, and innovative medical proce-
dures. The implicit agreement by the majority of society with the
inherent value of animal use for scientific purposes is reflected in
the laws permitting but protecting their use in almost every
country. Underpinning this legislation is the consensus that animal
experiments deserve major ethical consideration and such con-
siderations should be in balance with the moral consideration of
humans. This weighting of the costs (i.e., burden to the animal)
and benefits for the welfare of animals against the costs and
benefits for the welfare of humans (i.e., QOL) is described as a
utilitarian viewpoint, and this viewpoint dominates in Western
society. Such a viewpoint requires an understanding of the
severity and magnitude of the disease state affecting humans,
and also of the concept of animal welfare and its application to the
species used in biomedical research. Consideration of the welfare
of animals in biomedical research comprises the ethical responsi-
bility of the scientific community to: (1) ensure the potential
benefits arising from their use outweigh the burden placed on the
animals while establishing a boundary of acceptable animal use;
(2) ensure that any harm caused is as low as it can be and to strive
to achieve the highest level of well-being where animal use is
necessary. The concept of Replacement, Reduction and Refinement
as guiding principles for humane in vivo research was first
proposed in 1959 as a strategy to address this responsibility
(Russell and Burch, 1959). Since that time, the ‘3Rs’ concept has
become widely accepted as a robust ethical framework for redu-
cing animal use and suffering, helping to address societal concerns
about animal research. These guiding principles have prompted
investigators to replace animal experiments with alternatives
wherever possible, reduce the number of animals used per study
to the minimum consistent with the scientific objective, and refine
procedures or protocols to minimize any suffering that the animals
may experience. Table 1 presents a more detailed definition of
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each ‘R’ in relation to various general examples. There is interplay
between the 3Rs and conflicts can arise, such as when procedures
that enable a reduction in animal numbers lead to greater harm for
the fewer animals that are used (as might occur in a longitudinal
study using imaging, for example). This conflict is usually resolved
case-by-case by weighing the harms and benefits to the animals
involved, or else by prioritizing the experience of the animals (i.e.
refinement) over reduction.
Together the 3Rs provide a comprehensive means to reduce
harm to animals, but also have steadily evolved into an especially
meaningful tool in enhancing the overall scientific value for
investigators. Owing to the growing concern over translation,
there is increasing emphasis on animal model characterization to
better understand the usefulness and limitations of animal studies,
and strategies to improve agreement with the clinical situation to
improve prediction – these efforts are aligned with the 3Rs,
underscoring the importance of fully engaging with this ideology
and methodology.
In this manuscript we present a brief overview of certain
ethical principles underlying the use of animals in research and
discuss the key multifactorial role of the 3Rs in shifting the ethical
harm-benefit assessment. We give examples of how expertly
designed 3Rs methods not only reduce harms to animals but can
also expand our understanding of disease and strengthen scientific
outcomes to accelerate translation to the clinic to benefit patients.
2. Animal welfare in biomedical research: ethical basis for the
use of animals
There is general consensus with the view that animals do have
“moral standing”, and the central question of animal ethics there-
fore concerns: “What is the basis of our duties towards animals? And
what duties do we owe them?” (Sandøe et al., 1997). These
perspectives in animal ethics drive the animal welfare science
and public debate regarding the use of animals in biomedical
research. Evidently, such discussion can be extended to the many
other facets in which humans interact with animals, e.g., con-
servation in zoos, farming, hunting, companion use, entertainment
use, and service function. The present overview is intended only
for the context of sentient animals used in biomedical research. In
accord with the moral status of animals, there are essentially two
philosophical positions that dominate the debate over animal use,
the utilitarianism view and the animal rights view.
2.1. Utilitarianism
Utilitarianism implies a weighing of harms and benefits for
welfare of animals against harms and benefits for welfare of
humans (Sandøe et al., 1997). Utilitarianism has been most force-
fully defended by Singer (1989), who argued that what matters are
the interests of those being affected by what we do, independent
of whether it concerns the interests of humans or animals.
According to the utilitarianism point of view, the optimal solution
to an ethical dilemma is the solution in which the highest total
welfare is gained by all sentient parties concerned. Fundamentally,
utilitarianism is based on consequentialism, welfarism, and aggre-
gationism (Hare, 2009). Principles of utilitarianism are often
applied in medicine, ranging between the local level of institu-
tional review boards in assessing the harm-benefit profile of an
individual patient enrolling in a clinical trial, to a much higher
level in government approving medical products or procedures
based on harm-benefit profiles as applied to a population. As
outlined by Hare (2009):
 Consequentialism determines the moral quality of an action
(that is, determines what is right or wrong) based on the
consideration of its consequences,
 Welfarism considers the consequences that are relevant to the
morality of actions being the consequences that increase or
diminish the welfare of all those affected,
 Aggregationism refers to the distribution of welfare, i.e., a
solution should be sought that maximizes total welfare (i.e.,
when one outcome produces more welfare that is unequally
distributed, this outcome should be preferred above that with
less welfare that is equally distributed).
Aggregationism often leads to objections from those that think
equality of distribution alone matters, and cannot be sacrificed in
the maximization of total welfare (Singer, 1989).
2.2. The animal rights view
The animal rights view is similar to utilitarianism in that it
assumes humans and animals having comparable interests that
should be respected in comparable ways. Unlike utilitarianism
however, the animal rights view denies that we can justify
beneficial results by using immoral means (Sandøe et al., 1997),
which implies that the interests of one individual should never be
sacrificed for the benefits of the other. For example, as defended by
Regan, this ethical view would imply that one should never keep
Table 1
Definitions and examples of replacement, reduction and refinement.
‘R’ Definition Examples
Replacement Methods that avoid or replace the use of animals in areas where they would
have otherwise been used.
Human volunteers, tissues and cells; mathematical and computer models;
established animal cell lines, or cells and tissues taken from animals killed
solely for this purpose (i.e. not having been subject to a regulated
procedure); non-protected immature formsa of vertebrates; invertebrates,
such as Drosophila and nematode worms.
In some cases, relative replacement (i.e. replacing the use of live ‘protected’
vertebrates with vertebrate cells or tissues, early life-stages or non-
vertebrates) has been implemented as a first step to absolute replacement.
Reduction Methods that minimize the number of animals used per experiment or test,
either by enabling researchers to obtain comparable levels of information (of
a given amount and precision) from fewer animals, or to obtain more
information from the same number of animals (thereby avoiding further
animal use).
Improved experimental design and statistical analysis; sharing of data and
resources (e.g. animals and equipment) between research groups and
organizations; use of technologies, such as imaging, that enable
longitudinal studies in the same animals.
Refinement Methods that minimize any pain, suffering, distress or lasting harm that may
be experienced by the animals, and improve animal welfare. Refinement
applies to all aspects of animal use, from the housing and husbandry used to
the scientific procedures performed upon them.
Use of appropriate anesthetics and analgesics regimens; avoiding stress by
training animals to cooperate with procedures such as blood sampling;
providing animals with appropriate housing and environmental
enrichment which allows the expression of species-specific behaviors.
a In the European Union, non-protected immature forms are embryonic and fetal mammals, birds and reptiles up to the last third of their gestation or incubation period,
larval forms of amphibians and fish until they can feed independently, and cephalopods until the point at which they hatch.
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and/or use animals for biomedical research as it would violate the
rights of the animal to be only used a ‘means to an end’ (i.e., for the
sole purpose to achieve something else) (Regan, 1989). Both
utilitarianism and animal rights views suggest that nothing other
than the individual interests of humans and animals matter. A
more moderate advocacy of the animal rights view was suggested
by Sandøe et al. preserving a key notion “there are absolute, non-
negotiable limits to what can be done to animals” (Olsson et al.,
2010). They argue that one example of a non-negotiable limit
would be barring procedures that would inflict suffering involving
intense or prolonged pain or distress without relief and being
outside the control of the animal.
2.3. Applying animal ethics in biomedical research – the hybrid view
The ethical debate has been dominated by disagreements
between adherents to the utilitarian view (Singer) and adherents
to the animal rights view (Regan). Despite these apparent dis-
agreements, fundamental utilitarianism and animal rights views
appear far more alike each other than different (DeGrazia, 1998), in
agreement to provide the principle of equal consideration to both
animals and humans. In either case, these ethical views when
consequently enforced would result in radical changes in human-
animal relationships that would go beyond what is generally
considered “acceptable” in society. Thus, if the animal rights views
were consequently enforced, it would result in total rejection of
animal experiments. Utilitarianism is more nuanced: some adher-
ents accept animal experiments in the case that alternatives are
exhausted, and others like Singer suggest that an experiment be
justified only under highly extraordinary circumstances for human
health benefit.
Nowadays, utilitarianism is the dominating ethical approach in
practicing animal ethics in Western society, but it is rarely applied
in its “purist” form: thus, when ethical dilemma's in our moral
duty towards animals occur, the interest of humans is invariably
considered more important than that of animals (“speciesism”):
there are different opinions on the perspective of how the relative
importance of human interests relate to that of animals. Most
people take a “hybrid view” (Sandøe et al., 1997), in which
arguments from different ethical approaches are combined in a
pluralist utilitarian approach, in which ethical arguments are
weighed with respect to their relevance. In the example of
biomedical research, one might argue that a hybrid view is one
where elements from utilitarianism and animal rights are com-
bined: an example is the perspective that animals might be used
for disease research (utilitarianism), while at the same time a
certain accepted level of welfare should be guaranteed to allow
experimentation of animals irrespective of the benefit (animal
rights view). From the hybrid perspective, variable weights are
applied to different ethical arguments, and variable weights are
applied to human as opposed to animal interests.
What is the basis of our duties towards animals?
 Utilitarianism implies a weighing of harms and benefits for
welfare of animals against harms and benefits for welfare of
humans.
 The animal rights view assumes humans and animals having
comparable interests that should be respected in
comparable ways.
 The pluralist utilitarian approach suggests a hybrid view
where elements from utilitarianism and animal rights are
combined. Animals can be used for disease research
(utilitarianism), while at the same time a certain accepted level
of welfare should be guaranteed to allow experimentation of
animals irrespective of the benefit (animal rights view). This
view dominates Western society.
3. Harm-benefit analysis
3.1. Assessment of animal welfare (the benefit factor)
The pluralist utilitarian approach is arguably easier to follow in
translational research, where the main purpose is to develop
treatments for direct application in humans or animals suffering
from disease. In contrast, the practical benefits of using animals
tend to be more difficult to predict in the case of fundamental or
‘basic science’ research, because applications of any results are
further away from the research itself. Since the advancement of
science and technology requires both varieties of research to be
pursued, it is not necessarily fair to ask which type of research is
likely to deliver more benefit in the case where there is obvious
synergy. However, it is logical that different types of research are
open for consideration in different ways. Almost always, transla-
tional research has the characteristics that the potential benefit to
patients is well outlined, so that it should be more clear what
burden is reasonable to be placed on the animal: in contrast, the
ambiguity of basic research often makes judgment of harm-benefit
more difficult. In the situation of basic research, the achievement
of benefit is better limited to the likelihood of the research project
meeting its specific aims in generating new scientific knowledge
(Olsson et al., 2010). Because these experiments generally add
incremental knowledge to the overall field it is important to relate
the relevance of the research project to previous work, and any
benefits generated, in connection with the original contribution or
progress envisaged in the proposed work.
Even though the benefit anticipated from translational research
is usually easier to define it should certainly not be considered
automatic as issues related to model validity (e.g. improperly
characterized models or those that fail to faithfully represent the
clinical situation) can seriously compromise experiments
(McGonigle and Ruggeri, 2014;Denayer et al., 2014; van der
Worp et al., 2010). Evidently appropriate model selection, proper
study design, an experienced research team, and transparent
reporting of animal studies is necessary to realize the anticipated
benefit. Recognizing this, the ARRIVE (Animal Research: Reporting
of In Vivo Experiments) guidelines were developed in 2010 by the
NC3Rs to improve the quality of reporting of in vivo research to
maximize its value and minimize unnecessary animal use
(Kilkenny et al., 2010).
3.2. Assessment of animal welfare (the harm factor)
Animal welfare is an inclusive concept since there is both the
moral aspect of welfare reflecting the ethical use of animals and
then the empirical aspect that directly concerns the well-being of
the individual animal, as assessed by changes in physiology and
behaviour. In animals several factors have been suggested to be
included as relevant indications of well-being. Among the first
scientific definitions proposed were those of the Brambell Com-
mittee known as the ‘five freedoms’ (Brambell, 1965):
 freedom from thirst, hunger, and malnutrition
 freedom from discomfort
 freedom from pain, injury, and disease
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 freedom to express normal behavior
 freedom from fear and distress.
The literal application of the five freedoms in biomedical
research is complicated. For instance, there is a certain conflict
with ‘freedom from disease’ when considering that, fundamen-
tally, the model should closely resemble the disease it aims to
study (or aspects of it). Also, in a well-fit model situation there is
likely a conflict with ‘freedom from discomfort’, considering that
animals are only to be used when the need is justifiable based on
the suffering the disease inflicts on patients (e.g., it might be
difficult to completely avoid suffering in a disease state worth
modeling). The five freedoms are based on the suggestion that
absence of harm determines the presence of welfare. The defini-
tion has since evolved to acknowledge the presence of positive and
negative affective states in animals (Tannenbaum, 1991). Like in
humans, not just the absence of suffering but also the presence of
positive feelings is associated with well-being (Mench, 1998).
Broom simplifies this view concisely as the animal's “state as
regards its attempt to cope with its environment” (Broom, 1986)
which is further extended by Ohl in the context of evolutionary
adaption “Welfare as a biological function, embracing the con-
tinuum between positive and negative welfare, should take into
account the dynamics of the individual's adaptive capacity” (Ohl
and Van der Staay, 2012).
Also, continuing the discussion of ethics, several concepts have
been developed that refer to the kind of moral concern for
animals, going beyond the pure concept of animal welfare itself.
For instance:
 “intrinsic value” of animals refers to the idea that animals do not
have more “instrumental value” than humans, but also a value
in their own right (Brom, 1999).
 “flourishing” or “self-realization” refers to an interpretation of
animal welfare beyond that restricted to “absence of suffering”.
Apart from the animal's interest “not to suffer”, it is advocated
that animals should have the right to “flourish”, i.e., express all
capacities that the animal was designed for in an evolutionary
perspective (Brom, 1999).
With respect to the ethical concept of “intrinsic value”, the
concept has fulfilled an important, persuasive function in the
socio-political debate in the sense that introduction of the concept
has facilitated the consensus that animals are not mere “instru-
ments”, but have an importance and value of their own, irrespec-
tive of the value they have for humans and formed the basis for
more complex definitions of welfare.
Unlike animals used in other interactions with humans, ani-
mals in biomedical research often are not in a normal state, but
rather in a disease state relevant to the model or study interven-
tions. Because the state of disease generally violates the ‘good
health’ premise of welfare, it is relevant to examine welfare more
broadly and to consider the animal's experiences. Spruijt et al.
have described “Welfare is defined as the balance between
positive (reward, satisfaction) and negative (stress) experiences
or affective states. The state of this balance may range from
positive (good welfare) to negative (poor welfare). These affective
states are momentary or transient states which occur against the
background of and are integrated with the state of this balancing
Fig. 1. Effect of refinement on the harm-to-benefit ratio.
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system” (Spruijt et al., 2001). This definition has the important
consequence that lowering the level of negative stimuli does not
automatically bring the animal to a positive welfare state, but
opens the possibility that lowering (but not eliminating) exposure
to negative stimuli and increasing availability of positive stimuli
will result in a net positive effect – proper application of refine-
ment by investigators in animal models does exactly this
(Buchanan-Smith et al., 2005). When refinement is approached
in a multifactorial way that addresses the interests of the animal
while also promoting the scientific objective it avoids that animals
are simply used as a means to an end (i.e., the sole purpose of the
action is to achieve something else); instead it inherently respects
the intrinsic value of each animal as an individual with variable
experiences.
The practical assessment of harm should consider the severity
and duration of all potential adverse effects, physical and psycho-
logical (Fig. 1). This can involve the animal species, experimental
procedures, source of animals, transport, husbandry and care
conditions, quality of the facilities involved, and expertise of the
researchers (Smith et al., 2007). In animal models of disease,
subjects may experience symptoms, complications, and repeat
medical intervention similar to the clinical patient. In this situation
the potential for harm may be great, and careful application of
refined methods can decrease harms sufficiently in balance to
justify proceeding (Fig. 1).
Balancing harms against benefits
 The assessment of benefit in basic science is more difficult to
directly link to the intended clinical end goal. Therefore the
anticipated benefit should relate how the research will
incrementally contribute to fundamental scientific theory.
 The potential for benefit is great for translational research
aimed at treating diseases that substantially affect patient
quality of life. However harm can also be considerable as
animal welfare is intrinsically compromised in many animal
models of disease used to mimic the clinical situation for
safety and efficacy studies.
 When refinement is approached in a multifactorial way that
addresses the interests of the animal while also promoting the
scientific objective, the harm-benefit ratio is positively shifted.
4. Application of the 3Rs
4.1. Drivers for the 3Rs
Globally the practical protection of animals used in biomedical
research has taken the consideration of welfare to a higher level than
what is done in many other areas of human–animal interactions. The
3Rs principles (Table 1) are embedded in national and international
legislation and compulsory guidelines regulating the use of animals
for scientific purposes (e.g. European Parliament and the Council of
the European Union, 2010; Administration of Quality Supervision,
Inspection and Quarantine of the People's Republic of China and
Standardization Administration of the People’s Republic of China,
2013; Ministry of Environment and Forestry India, 2013; United
States Department of Agriculture, 2013) as well as local oversight (e.
g., in the form of ethics committees), and also voluntary standards
like in accreditation by Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC) of an institution
(AAALAC, 2014). International guidelines on the use of animals for
regulatory purposes are also increasingly making recommendations
and developing processes that contribute to the 3Rs (e.g. those from
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use)
(Ohno, 2002). Many industry companies now highlight the 3Rs as
part of their corporate social responsibility (e.g. AstraZeneca, 2014;
Unilever, 2014; Novartis, 2014; GlaxoSmithKline, 2014).
Regardless of positioning, either in industry or academic and
knowledge institutions, it is the responsibility of the ethics
committee to ensure the 3Rs are implemented locally. The over-
arching task of ethical review by ethics committees, for example
the Institutional Animal Care and Use Committees (IACUC) in the
US or Animal Welfare and Ethical Review Bodies (AWERB) in the
UK, is to translate principles of animal welfare into the wellbeing
of animals during experimental protocols as well as to act on
behalf of the institution to critically review study protocols and
ensure the research involving animals is justified by the benefits.
The full charge of the IACUC is extensively detailed in the Guide for
the Care and Use of Laboratory Animals (Janet et al., 2011). The
“Guide” forms the basis also for institutions to pursue AAALAC
accreditation, which is a voluntary process in which “research
programs demonstrate that they meet the minimum standards
required by law, and are also going the extra step to achieve
excellence in animal care and use” (AAALAC, 2014).
Beyond the concern of the committees and government,
opinion polls consistently show that important public support
for in vivo research is conditional on the demonstration of the
benefits of animal research in combination with humane experi-
mental techniques and full application of the 3Rs (e.g. Ipsos MORI,
2014).
Historically the 3Rs were viewed primarily in the context of
stewardship and animal welfare science. Nowadays the 3Rs
principles are increasingly implemented within mainstream scien-
tific practice as they are recognized as another tool that supports
study design and interpretation (e.g. statistics). A key driver for
this is the growing appreciation of the real opportunities provided
by the 3Rs for supporting high quality science, improving business
efficiency, and addressing some of the major challenges currently
facing pharmaceutical and chemicals companies worldwide. The
3Rs can benefit not just animal welfare, but also human health, the
environment and the economy.
The scientific imperative for developing new, robust appr-
oaches to research and development is very strong. Although the
use of animals forms a major part of much biomedical research,
success seen in animal studies has not always translated to the
clinic. A high percentage of drug candidates are removed from
development when tested in humans because of a lack of efficacy
or safety that was not predicted in animal tests, with oncology,
infectious disease and neuroscience indications having the highest
attrition rates (Kola and Landis, 2004; Walker and Newell, 2008;
Bailey et al., 2014). Reducing attrition, even by a small amount, can
lead to huge financial savings and increased business growth.
Hence initiatives are underway to develop new methods to screen
failures out as early as possible and to select, with further research
and development, those approaches most likely to succeed (e.g.
Europe's Innovative Medicines Initiative and the FDA's Critical Path
Initiative). Similarly, there are concerns about the utility of animal
studies for testing environmental chemicals (Leist et al., 2008). For
example, animals are invariably exposed to much higher doses
than typical human exposures making interpretation difficult.
Organizations such as the National Research Council and OECD
(National Research Council, 2007; Leist et al., 2008; Organisation
for Economic Co-operation and Development, 2013) have called
for the development of mechanism-based assays that are more
predictive of human biology, and increasingly attention has
focused on in vitro and in silico approaches based on human
material for solutions. There are also concerns about the reprodu-
cibility of academic science, which many pharmaceutical compa-
nies rely on for target identification and validation. For example, in
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2012 scientists from Amgen and the University of Texas M.D.
Anderson Cancer Center reported in Nature their attempts to
confirm findings from 53 ‘landmark’ papers in the preclinical
cancer field (Begley and Ellis, 2012). Eighty-nine percent of the
studies described, the majority of which used animals, could not
be reproduced with poor study design, investigator bias and
incomplete reporting identified as major contributing factors.
Similar findings have been reported for preclinical research in
other disease areas (Table 2). The issues are not the same in every
case but in general there is a need for greater methodological rigor
(e.g. Randomization and blinding) to reduce bias and improve
internal validity, more clinically relevant models, assays and out-
come measures, and more comprehensive reporting within the
literature. Funders such as the US National Institutes of Health and
UK Medical Research Council, and journals such as the Nature and
PLoS families, have committed to address the issues raised. As a
first step, many have endorsed the ARRIVE guidelines (Kilkenny et
al., 2010).
4.2. An emphasis on 3Rs science
There are a number of organizations globally that focus on the
3Rs as an aspect of laboratory animal care (e.g. American Associa-
tion for Laboratory Animal Science, Institute for Laboratory Animal
Research, International Council for Laboratory Animal Science,
AAALAC, and Federation of European Laboratory Animal Science
Associations) (Griffin et al., 2014). In the UK, the pioneering
National Centre for the Replacement, Refinement and Reduction
of Animals in Research (NC3Rs) has been central to shifting
mindsets within the scientific community and accelerating the
development and application of all 3Rs. It directly appeals to
scientists by funding research and early career development,
supporting open innovation and the commercialization of 3Rs
technologies, and providing opportunities to partner to address
specific challenges faced by scientists in specific fields (e.g. use of
chronic implants in neuroscience studies with non-human
primates).
There is now much more focus with academia and industry on
developing alternative approaches that avoid the use of animals
and provide better tools for modeling human biology and disease.
An exciting pipeline of technologies with 3Rs potential is emerging
from the academic science base, including stem cell technologies,
3D tissue constructs and bioprinting, organ-on-chips and micro-
fluidics, advanced in vitro and in vivo imaging, and mathematical
and in silico modeling. These are benefiting animals but also the
scientific community, facilitating scientific progress in a virtuous
circle (Fig. 2). The need to improve the design, conduct and
analysis of in vivo research is also gathering momentum, with
greater emphasis on minimizing animal use and improving animal
welfare. Knowledge about animals' physical and behavioral
requirements, and the welfare impact of scientific procedures, is
expanding rapidly and being translated into practical information
to minimize pain and distress and improve the robustness and
reproducibility of animal experiments. For example, novel hand-
ling methods for mice which avoid the high anxiety and variation
associated with traditional methods (Hurst and West, 2010), use of
‘grimace scales’ to assess post-surgical pain in animals, so that it
can be alleviated and its potentially confounding effects removed
(Keating et al., 2012; Leach et al., 2012), and provision of environ-
mental enrichment to satisfy species-typical needs, reduce abnor-
mal behaviour, and improve environmental construct validity
(Martin et al., 2010; Burrows et al., 2011; Bayne and Wurbel, 2014).
Importance of the 3Rs
 The 3Rs principles are embedded in national and international
legislation and compulsory guidelines regulating the use of
animals for scientific purposes as well as local oversight
mechanisms (e.g., ethics committees), and also voluntary
standards such as institutional accreditation by AAALAC.
 The 3Rs are an integral part of conducting high quality
bioscience, and a means of addressing issues of major
importance currently facing the academic, pharmaceutical and
chemicals sectors, such as poor reproducibility of animal
studies and high rates of attrition in drug development. The
3Rs can benefit not just animal welfare, but also human health,
the environment and the economy.
 A wide range of cutting edge technologies is being used to
develop robust tools and approaches for the study of human
biology, diseases, and treatments with reduced reliance on
animal use and/or improved animal welfare.
5. The essential role of the investigator
Tannebaum suggests that reluctance by investigators to engage
in ethical assessment of animal research follows from thinking
that their scientific background does not qualify them, but
reminds us “the pain and distress minimization principle cannot
be applied correctly to an animal research project without knowl-
edge and expertise possessed uniquely by scientists who are
familiar with the kinds of questions asked by the project, the
applicability to these questions of various kinds of experiments or
research techniques, the nature and effects of possible ways of
using the animals on what they experience, and techniques for
preventing or minimizing their pain or distress. These are all
matters of science and not ethical theory (Tannenbaum, 2013)”.
The 3Rs principles cannot be applied correctly to an animal
experiment without the knowledge base possessed uniquely by
the scientists familiar with the research question, underscoring
their critical role to realize the full potential of the 3Rs. All
Table 2
Examples of papers citing the limitations of animal studies.
Disease/research area Reference
Asthma Holmes et al. (2011), Abbott-Banner et al. (2013), Mullane and Williams (2014), Mercer et al. (2015)
Cancer De Bono and Ashworth (2010), Begley and Ellis, (2012), Moreno and Pearson (2013), Ruggeri et al. (2014)
CNS disorders McGonigle (2014)
Emetic liability du Sert et al. (2012)
Epilepsy Löscher (2011)
Multiple sclerosis Friese et al. (2006), Mix et al. (2010), Pachner (2011), Baker et al. (2011)
Pain Percie du Sert and Rice (2014)
Sepsis Webb (2014)
Stroke Crossley et al. (2008), Mergenthaler and Meisel (2012), Sena et al. (2010), van der Worp et al. (2010), Howells et al. (2014)
Transplantation Graham and Schuurman (2013), Wijkstrom et al. (2013)
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scientists should appreciate the relevance of the 3Rs to their work,
especially from the perspective of validity, and to be aware of the
latest developments in the 3Rs that relate to their research field
and how they can contribute to these.
As individuals responsible for the design and conduct of
research, investigators have a crucial role to play in implementa-
tion of the 3Rs. Most regulatory systems for the protection of
animals in science place the onus on the investigator to apply the
3Rs when selecting models and approaches to be used for basic
and applied research, regulatory testing, and education and train-
ing, with assistance and oversight provided by the institutional
ethics committee (IACUC or AWERB). In a well-run animal facility,
investigators, their scientific peers (not necessarily within the
same discipline), the attending veterinarian and animal care staff
will adopt a team approach, working together on the identifica-
tion, application and review of 3Rs methods. Ideally this should
begin with an evaluation of the availability of approaches to avoid
or limit animal use. As new knowledge, technologies and
approaches emerge there should be timely assessment and evolu-
tion of scientific and husbandry practices, research strategies and
study designs to meet best practice. Sources of contemporary
information and advice include the NC3Rs website (www.nc3rs.
org.uk), Altweb site from John Hopkins Center for Alternatives to
Animal Testing (http://altweb.jhsph.edu/) and the European Com-
mission's database on alternative methods, DB-ALM (http://
ecvam-dbalm.jrc.ec.europa.eu/beta/) is one.
In addition to the implementation of existing 3Rs methods,
there are exciting opportunities open to investigators to contribute
to the ambitious challenge of developing novel research models
and tools aimed at reducing animal use and improving animal
welfare. Such research is now a legitimate scientific goal in its own
right, and provides new opportunities for funding, technological
innovation, multidisciplinary collaboration and publishing. Inves-
tigators in the biosciences should consider applying to the com-
petitive funding schemes available within their region (e.g. UK
NC3Rs, www.nc3rs.org.uk, EU Horizon 2020, http://ec.europa.eu/
programmes/horizon2020/). Nor is progress in the 3Rs limited to
technological development and hypothesis driven research. There
are opportunities to join in with pre-competitive data sharing to
identify optimized study designs and protocols and to generate an
evidence base to stimulate changes in policy, regulations and
practice (Chapman et al., 2013; Robinson et al., 2008; Prescott
et al., 2010).
Once developed these new research models and tools need to
be published, disseminated and widely adopted in order to achieve
major reductions in animal use and improvements in animal
welfare. This requires investigators reviewing manuscripts and
grant applications, and those conducting in vivo research, to have
an open mind and be receptive towards novel approaches. For
academic scientists in particular, who have built their careers on
specific animal models, changing to a new, gold standard model
(animal or non-animal) can be daunting, even where there is
evidence to suggest the alternative approach is superior. However,
the incentives include more informative and/or clinically relevant
models (Tymvios et al., 2008; Moore and Emerson, 2012; Lidster et
al., 2013), more rapid screening tools with improved sensitivity
and/or specificity (Persaud et al., 2010; Redhead et al., 2012; Vinci
et al., 2012; Walmsley and Tate, 2012) and the possibility of
discoveries that would not otherwise be made using traditional
models. For example, Williams and colleagues have used the social
amoeba, Dictyostelium discoideum, to elucidate the mechanism of
action of sodium valproate, the most widely prescribed drug for
epilepsy treatment, and to identify new fatty acids and fatty acid
derivatives with more potent anti-epileptic activity (Terbach et al.,
2011; Chang et al., 2012).
5.1. Experimental design and reporting standards
Numerous surveys have documented serious omissions in the
reporting of animal-based studies (e.g. Kilkenny et al., 2009). To
make their work more transparent and reproducible, investigators
should report in accordance with the ARRIVE guidelines (Kilkenny
et al., 2010), as is recommended/required by over 430 scientific
journals and the major UK bioscience funding bodies. The guide-
lines and supporting resources, such as a checklist and presenta-
tion with speaker notes, are available on the NC3Rs website (www.
nc3rs.org.uk/arrive-guidelines). More comprehensive reporting
should have the added benefit of making systematic reviews and
meta-analyses of in vivo research more feasible (Hooijmans et al.,
2011; Leenaars et al., 2011). This can lead to 3Rs impacts, such as
supporting a reduction in animal numbers, determining whether
high severity tests, multiple tests or higher species are necessary,
and avoiding the use of uninformative models or those that do not
translate. The NC3Rs is facilitating the wider use of systematic
reviews and meta-analyses by researchers for 3Rs purposes by
supporting the CAMARADES consortium (www.dcn.ed.ac.uk/
camarades/default.htm).
Scientists, especially those trained extensively in in vitro techni-
ques, may not have access to training for or expertise in experi-
mental design or statistical analysis of animal experiments and as a
result may use too many or too few animals, both of which are
unethical, or analyze and interpret data incorrectly. Often group
sizes are based on what has previously been used or what has been
reported in the literature without a rigorous evaluation, and there is
a lack of awareness of strategies to avoid bias. To help address these
issues and support investigators that lack institutional access to
professional statistical support, the NC3Rs is developing the Experi-
mental Design Assistant, an online, knowledge-based system avail-
able to all scientists and amenable to a wide range of research areas
(www.nc3rs.org.uk/experimental-design-assistant-eda). The NIH is
Fig. 2. Virtuous circle of the 3Rs and scientific progress.
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supporting training courses targeted at graduate scientists, post-
doctoral fellows and beginning investigators (http://grants.nih.gov/
grants/guide/rfa-files/RFA-GM-15-006.html).
Investigators and the 3Rs
 The 3Rs principles cannot be applied correctly to an animal
experiment without the knowledge base possessed uniquely
by the scientists familiar with the research question.
 Funding schemes exist for the development, validation and
commercialization of new 3Rs methods, providing
investigators with new opportunities for research funding,
technological innovation, multidisciplinary collaboration and
publishing.
 New research models, tools, and approaches need to be
published, disseminated and widely adopted in order to
achieve major reductions in animal use and improvements in
animal welfare. This requires investigators reviewing
manuscripts and grant applications, and those conducting
in vivo research, to embrace the 3Rs framework and have an
open mind towards novel approaches.
 Inadequate reporting of key aspects of the design and analysis
of in vivo research can act as a barrier to translation by
preventing repetition or inclusion in meta-analysis.
Investigators should report animal-based studies in
accordance with the ARRIVE guidelines.
6. 3Rs use to reduce harm to animals and increase
translational value
There are many examples of application of the 3Rs that
demonstrate improved animal well-being and scientific benefit
do not conflict with each other, but can act in synergy to improve
the translational value of the model. This is highly relevant in
convincing the scientific community that model design, support,
and validation is worthy of at least as much attention as the
scientific question they study.
6.1. 3D tumor spheroids for target validation and drug evaluation
Substantial advances in three-dimensional (3D) culture sys-
tems have improved agreement with the tumor microenviron-
ment in vivo to replace use of mice in early screening of anticancer
agents. Eccles and colleagues have developed a toolkit of 3D tumor
spheroid models to support high throughput preclinical studies
(Vinci et al., 2012). Prior to their development of the 3D culture
toolkit many animals were used without legitimate in vitro valida-
tion since 2D tumor cell cultures are not sufficiently predictive of
in vivo response. The toolkit provides more predictive in vitro
functional assays of cell growth, motility, tissue invasion and
angiogenesis that have improved early drug evaluation and
replaced a significant proportion of animals used alongside 2D.
6.2. Moving away from thromboembolic mortality as a model of
pulmonary embolism
A striking example of reduction of animals has been achieved
in the mouse model of pulmonary embolism by Emerson and
colleagues. Platelet-dependent thrombosis is a major factor in
heart attack and stroke and studied extensively in mouse models
capable of modeling physical factors like blood flow, shear stress,
and vascular endothelial cell mediators (Tymvios et al., 2009).
Conventional modeling relies on injection of thrombogenic sub-
stances in conscious animals that often results in paralysis and
death. In contrast, Emerson's refined model is performed under
general anesthesia using radiolabeled platelets and imaging to
measure platelet function in real time during non-fatal throm-
boembolism (Tymvios et al., 2009). Not only were they successful
in strengthening the model by broadening the spectrum beyond a
single extreme (i.e. fatal pulmonary embolism) and measuring a
specific biological response rather than events with non-specific
causes, but also they were able to reduce the number of mice per
experiment by around 90% (Emerson, 2010).
6.3. Neuroprotection in a novel mouse model of multiple sclerosis
Disease models typically place a considerable burden on
animals from the perspective of symptoms resulting from the
disease, but also in disease monitoring and application of experi-
mental therapies. Extensive characterization of animal models
(Table 2) is a key driver for refinement. Baker and colleagues
recently developed a highly innovative refined mouse model of
multiple sclerosis (MS) that avoids substantial suffering of animals
(e.g. progressive ascending paralysis) associated with conventional
autoimmune encephalomyelitis models (Lidster et al., 2013). Like-
wise they identified limitations in the conventional model, in that
it primarily represented central nervous system inflammation but
not other immune-independent mechanisms of neurodegenera-
tion (Baker et al., 2011). Their approach induces optic neuritis
(ON), the presenting feature in the majority of MS patients, to
model axonal loss and neurodegeneration characteristic in MS.
This has special scientific relevance, as disease progression can be
monitored serially using non-invasive clinically relevant techni-
ques, key in evaluating neuroprotective strategies. From the
perspective of animal wellbeing, instead of paralysis the resulting
disability from disease is visual sensory loss that is much better
tolerated in rodents already evolved for nocturnal behaviors
(Lidster et al., 2013).
6.4. Holistic refinement in nonhuman primate diabetes models
Diabetic animal models are another example of disease models
where the burden to animals is substantial since animals require
intensive clinical monitoring and medical care. These experiments
should be run under conditions of optimal refinement. In induced
models the method for disease induction must reliably result in
disease while minimizing risk to the animal (Graham et al., 2011a,
2011b). Refinements techniques should also be used improve
disease management, introduce features into the model to make
it more ‘clinical trial-like’, or to avoid model-induced confounding,
e.g. preventing nephro- and hepato- toxicity in streptozotocin-
induced animals (Graham et al., 2012, 2010). The primary outcome
measure in diabetes studies is often a stress sensitive metabolic
parameter (e.g. blood glucose) so refined animal handling techni-
ques are imperative (Lapin et al., 2013; Shirasaki et al., 2013;
Gartner et al., 1980). Nonhuman primates are extensively used in
to study β-cell replacement strategies (e.g. islet cell transplanta-
tion), for reasons described in depth elsewhere in this issue, and
can be trained to cooperate with and facilitate their medical care
while remaining in the familiar homecage using counter condi-
tioning and positive reinforcement techniques (Graham et al.,
2010). The scientific community is relatively clear on the aspect
of refinement that attempts to lower the negative experiences of
the animal but less so in the more progressive interpretation that
seeks to also increase positive experiences for the animal to
flourish. Training complex behaviors to NHPs is an important
opportunity for the animals to engage in challenge, apply cognitive
skills to decide actions, be active participants in their environ-
ments and reduce stress. Noteworthy is the fact that most ‘stress
hormones’ have immunosuppressive activity and certainly
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considered a confound in studies aimed at evaluating immune
response to transplanted tissue (Graham and Schuurman, 2013).
Glucocorticosteroids might be among the best examples and are
well known for their direct and chronic effect on thymus histology.
Interestingly the presence of acute or chronic involution in thymic
histology was significantly reduced in diabetic and immunosup-
pressed NHPs trained for cooperation. The use of refinement
techniques in this model was successful both in significantly
reducing model-induced adverse events affecting animal well-
being and also in eliminating certain confounding variables that
interfere with proper safety and efficacy evaluation of cell therapy
products and immunosuppressive regimens (Graham and
Schuurman, 2013).
Application of the 3Rs
Practical application of the 3Rs can accelerate and improve
translation. The model design, application, and validation is
worthy of at least as much attention as the scientific question
under study.
7. Conclusion and perspectives
While focused primarily on the ethical imperative to minimize
harm to animals in science, in developing the 3Rs, Russell and
Burch also maintained that scientific excellence and the humane
use of laboratory animals are inextricably linked. Although there is
general agreement that improving the welfare of the animal
enhances the quality of research, the 3Rs should be viewed even
one level higher; this level includes the possibility that proper
application of the 3Rs not only improves animal welfare but also
enhances the ‘model agreement’ or translational value of the
research. This combination approach towards the 3Rs seems
essential to engage scientists in a more meaningful way with the
3Rs in practice. It is reasonable to expect that any animal model
will have some degree of limitation, but proper experimental
design and characterization plus detailed understanding of limita-
tions allows for development of replacement alternatives or
refinement of in vivo models towards a closer agreement with
the human situation. Taking this step further can improve the
predictive value of models, such that the translational power is
increased and, in the case of animal based models, the contribu-
tion of the animal is maximized.
Better and more consistent application of the 3Rs is considered
a major opportunity for “scientific, economic, and humanitarian”
cross-benefit (Zurlo et al., 1996). Already in the mid-1990s parti-
cipants in the Sheringham workshop made several very good
recommendations towards this goal, especially highlighting the
need to harmonize the incorporation of the 3Rs into various legal
frameworks across nations, provide 3Rs-specific training, and also
the need for international discussion and agreement on practical
implementation of harm-benefit analysis (Zurlo et al., 1996).
Considering the urgent need to accelerate translation, application
of the 3Rs should be given a very high priority by scientists and
regulators.
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